Stockholm:NVP

NeuroVive Pharmaceutical AB Year End Report January - December 2019

STOCKHOLM, Feb. 19, 2020 /PRNewswire/ -- Important events in 2019 KL1333            * NeuroVive enrolls first subject in its European KL1333 phase Ia/b clinical study            * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study            * NeuroVive compl...

2020-02-19 16:08 5212

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

LUND, Sweden, Dec. 23, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the completed recruitment of healthy volunteers in the second part of the company's ongoing Phase Ia/b clinical study with candidate drug KL1333, in development for chroni...

2019-12-23 08:33 544

NeuroVive Announces Settlement in Dispute With CicloMulsion AG

LUND, Sweden, Dec. 16, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that it has fully and finally settled the dispute with CicloMulsion AG regarding certain pharmaceutical technology. In 2004, NeuroVive entered into a License Agreement wi...

2019-12-16 18:33 5235

NeuroVive Pharmaceutical AB Interim Report January - September 2019

STOCKHOLM, Nov. 20, 2019 /PRNewswire/ -- Important events July - September * NeuroVive initiates second part of its ongoing KL1333 Phase Ia/b clinical study * NeuroSTAT receives Fast Track designation from the US Food and Drug Administration. Financial information third quarter (July-Septem...

2019-11-20 16:38 2785

NeuroVive Pharmaceutical AB Interim Report January - June 2019

STOCKHOLM, Aug. 21, 2019 /PRNewswire/ -- Important events April - June * The US Food and Drug Administration, FDA, approves NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT. * The Supreme Court delivers it...

2019-08-21 15:24 7050

NeuroVive's NeuroSTAT Project Receives FDA Fast Track Designation

LUND, Sweden, July 28, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company's candidate drug NeuroSTAT, in development for treatment of moderate to severe traumatic brain injury, TBI, has received Fast Track designation from the ...

2019-07-28 21:47 4238

NeuroVive Initiates Second Part of its Ongoing KL1333 Phase Ia/b Clinical Study

LUND, Sweden, 4 July 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the company has initiated the second part in its ongoing Phase Ia/b clinical study with KL1333, NeuroVive's candidate drug for chronic treatment of genetic mitochondri...

2019-07-04 21:05 7848

NeuroVive's IND for Clinical Development of NeuroSTAT Approved by FDA

LUND, Sweden, May 10, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that the US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's ...

2019-05-10 15:05 4687

NeuroVive Pharmaceutical AB Publishes 2018 Annual Report

LUND, Sweden, 25 March 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the English version of the Annual report for 2018 is now available on the company's website  www.neurovive.com

2019-03-25 17:58 6131

NeuroVive Enrolls First Subject in its KL1333 Phase Ia/b Clinical Study

LUND, Sweden, March 19, 2019 /PRNewswire/ -- NeuroVive Pharmaceutical AB  (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the first healthy volunteer in the company's KL1333 phase Ia/b study has been screened and will be enrolled into the study. First subject first visit in NeuroVive's...

2019-03-19 15:58 490

NeuroVive Receives Vinnova Funding to Support Development of NV354, a Novel Treatment for Genetic Mitochondrial Disorders

LUND, Sweden, Nov. 15, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) announced today that the company has been awardedSEK 1.5 million as a first tranche of total SEK 5 million in funding from Vinnova,Sweden's innovation agency, and the Swelife call, for i...

2018-11-15 19:37 647

NeuroVive Receives KL1333 Clinical Trial Regulatory Approval

LUND, Sweden, Oct. 10, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that it has received approval of its clinical trial application concerning a planned phase I KL1333 study in patients and healthy volunteers from the UK regulatory author...

2018-10-10 14:49 591

NeuroVive Reports First NeuroSTAT Clinical Efficacy Signal in TBI

LUND, Sweden, Oct. 4, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the successful completion of biomarker analyses of samples from its clinical study in severe traumatic brain injury patients (the CHIC study) using the company's investigat...

2018-10-04 15:43 630

NeuroVive Receives Positive FDA Feedback on its NeuroSTAT TBI Development Plan

LUND, Sweden, Sept. 6 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical development plan for the treatment of moderate to severe Traumatic Brain Injury (TBI) a...

2018-09-06 15:10 743

NeuroVive's NVP015 Program Will be Accelerated Through Award of Major Research Grant to Children's Hospital of Philadelphia

LUND, Sweden, Aug. 28, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) today announced that scientists at the company's research partner the Children's Hospital ofPhiladelphia (CHOP) have received a three-year grant (W81XWH-17-PRMRP-TTDA), in total of$4,090...

2018-08-28 15:21 809

NeuroVive Pharmaceutical AB Interim Report January - June 2018

STOCKHOLM, Aug. 21, 2018 /PRNewswire/ -- Important events January-June 2018 * NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma's new subsidiary Fortify Therapeutics. The agreement has a total potential value of approximately$60 million USD including any royalties. * NeuroVive ...

2018-08-21 15:22 1117

NeuroVive Out-licenses Targeted LHON Therapy to BridgeBio Pharma's New Subsidiary Fortify Therapeutics

LUND, Sweden and PALO ALTO, Calif., June 19, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an exclusive licensing agreement for a subset of succinate prodrug chemistry under Neuro...

2018-06-19 04:39 716

Amended Number of Shares and Votes in NeuroVive Pharmaceutical AB (publ)

LUND, Sweden, May 31, 2018 /PRNewswire/ --NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF),the mitochondrial medicine company, today announced an increase of the number of shares and votes in NeuroVive of 39,244,644 as a result of a preferential rights issue in NeuroVive Pharma...

2018-05-31 20:09 1227

NeuroVive Pharmaceutical AB Interim Report January - March 2018

STOCKHOLM, May 22, 2018 /PRNewswire/ -- Successful rights issue Business operations Important events January – March 2018 * NeuroVive decided to conduct a rights issue for the continued development of the company's drug projects following shareholder approval at an Extraordinary General Meeti...

2018-05-22 15:22 1019

NeuroVive and Yungjin Reports Positive KL1333 Phase I Clinical Study Results Paving the way for Further Clinical Development

LUND, Sweden and SEOUL, South Korea, May 21, 2018 /PRNewswire/ -- NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP) (OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly announced positive topline results after data base lock in the phase I single...

2018-05-21 17:26 887
1234